Gallicchio R, Scapicchio D, Nardelli A, Pellegrino T, Prisco M, Mainenti P, Sirignano C, Pedicini P, Storto G
Assessment of residual radioactivity by a comprehensive wireless, wearable device in thyroid cancer patients undergoing radionuclide therapy and comparison with the results of a home device: a feasibility study
Ieee J Transl Eng Health Med (ISSN: 2168-2372linking), 2020 Dec 2; 9: 2700306-2700306.

Faggiano A, Modica R, Severino R, Camera L, Fonti R, Del Prete M, Chiofalo MG, Aria M, Ferolla P, Vitale G, Pezzullo L, Colao A
The antiproliferative effect of pasireotide LAR alone and in combination with everolimus in patients with medullary thyroid cancer: a single-center, open-label, phase II, proof-of-concept study
Endocrine (ISSN: 1355-008xlinking), 2018 Oct; 62(1): 46-56.

Russo M, Malandrino P, Moleti M, Vermiglio F, D'Angelo A, La Rosa G, Sapuppo G, Calaciura F, Regalbuto C, Belfiore A, Vigneri R, Pellegriti G
Differentiated thyroid cancer in children: Heterogeneity of predictive risk factors
Pediatr Blood Cancer (ISSN: 1545-5009linking), 2018 Sep; 65(9): e27226-e27226.

Greco A, Auletta L, Orlandella FM, Iervolino PLC, Klain M, Salvatore G, Mancini M
Preclinical Imaging for the Study of Mouse Models of Thyroid Cancer
Int J Mol Sc (ISSN: 1422-0067, 1661-6596, 1422-0067linking), 2017 Dec 16; 18(12): 1-18.

Mazziotti G, Formenti AM, Panarotto MB, Arvat E, Chiti A, Cuocolo A, Dottorini ME, Durante C, Agate L, Filetti S, Felicetti F, Filice A, Pace L, Pellegrino T, Rodari M, Salvatori M, Tranfaglia C, Versari A, Viola D, Frara S, Berruti A, Giustina A, Giubbini R
Real-life management and outcome of thyroid carcinoma-related bone metastases: results from a nationwide multicenter experience
Endocrine (ISSN: 1355-008x, 1355-008xlinking), 2017 Nov 06; 59(1): 90-101.

Tavarelli M, Malandrino P, Vigneri P, Richiusa P, Maniglia A, Violi MA, Sapuppo G, Vella V, Dardanoni G, Vigneri R, Pellegriti G
Anaplastic Thyroid Cancer in Sicily: The Role of Environmental Characteristics
Front Endocrinol (ISSN: 1664-2392, 1664-2392linking), 2017 Oct 20; 8: 277-277.

Salvatore B, Klain M, Nicolai E, D'Amico D, De Matteis G, Raddi M, Fonti R, Pellegrino T, Storto G, Cuocolo A, Pace L
Prognostic role of FDG PET/CT in patients with differentiated thyroid cancer treated with 131-iodine empiric therapy
Medicine (ISSN: 0025-7974), 2017 Oct; 96(42): e8344-e8344.

Sapuppo G, Palermo F, Russo M, Tavarelli M, Masucci R, Squatrito S, Vigneri R, Pellegriti G
Latero-cervical lymph node metastases (N1b) represent an additional risk factor for papillary thyroid cancer outcome
J Endocrinol Invest (ISSN: 1720-8386, 0391-4097, 1720-8386electronic), 2017 Jun 23; N/D: N/D-N/D.

Russo M, Malandrino P, Moleti M, Vermiglio F, Violi MA, Marturano I, Minaldi E, Vigneri R, Pellegriti G, Regalbuto C
Tall cell and diffuse sclerosing variants of papillary thyroid cancer: outcome and predicting value of risk stratification methods
J Endocrinol Invest (ISSN: 1720-8386, 0391-4097, 1720-8386electronic), 2017 May 20; 40(11): 1235-1241.

Russo M, Malandrino P, Moleti M, D'Angelo A, Tavarelli M, Sapuppo G, Giani F, Richiusa P, Squatrito S, Vigneri R, Pellegriti G
Thyroid Cancer in the Pediatric Age in Sicily: Influence of the Volcanic Environment
Anticancer Res (ISSN: 0250-7005, 0250-0700, 0250-7005linking), 2017 Mar; 37(3): 1515-1522.

Pacifico F, Lepore A, Mellone S, Sanguigno L, Federico G, Greco A, Brunetti A, Leonardi A
The chemokine scavenging receptor D6/ACKR2 is a target of miR-146a in thyroid cancer
Genes Cancer (ISSN: 1947-6019), 2017; 8(5-6): 577-588.

Vigneri R, Malandrino P, Giani F, Russo M, Vigneri P
Heavy metals in the volcanic environment and thyroid cancer
Mol Cell Endocrinol (ISSN: 0303-7207), 2016 Oct 26; N/D: N/D-N/D.

Malandrino P, Russo M, Regalbuto C, Pellegriti G, Moleti M, Caff A, Squatrito S, Vigneri R
Outcome of the Diffuse Sclerosing Variant of Papillary Thyroid Cancer: A Meta-Analysis
Thyroid (ISSN: 1050-7256, 1050-7256linking), 2016 Sep; 26(9): 1285-1292.

Malandrino P, Russo M, Ronchi A, Minoia C, Cataldo D, Regalbuto C, Giordano C, Attard M, Squatrito S, Trimarchi F, Vigneri R
Increased thyroid cancer incidence in a basaltic volcanic area is associated with non-anthropogenic pollution and biocontamination
Endocrine (ISSN: 1355-008x, 1355-008xlinking), 2016 Aug; 53(2): 471-479.

Marotta V, Di Somma C, Rubino M, Sciammarella C, Modica R, Camera L, Del Prete M, Marciello F, Ramundo V, Circelli L, Buonomano P, Colao A, Faggiano A
Second-line sunitinib as a feasible approach for iodine-refractory differentiated thyroid cancer after the failure of first-line sorafenib
Endocrine (ISSN: 1355-008x), 2015 Aug; 49(3): 854-858.

Pace L, Klain M, Salvatore B, Nicolai E, Zampella E, Assante R, Pellegrino T, Storto G, Fonti R, Salvatore M
Prognostic Role of 18F-FDG PET/CT in the Postoperative Evaluation of Differentiated Thyroid Cancer Patients
Clin Nucl Med (ISSN: 0363-9762, 1536-0229, 1536-0229electronic), 2015 Feb; 40(2): 111-115.

Pace L, Klain M, Salvatore B, Nicolai E, Zampella E, Assante R, Pellegrino T, Storto G, Fonti R, Salvatore M
Prognostic Role Of 18f-Fluorodeoxyglucose Positron Emission Tomography/Ct In The Postoperative Evaluation Of Differentiated Thyroid Cancer Patients
Clin Nucl Med (ISSN: 0363-9762, 1536-0229, 1536-0229electronic), 2015 Feb; 40(2): 111-115.

Gallicchio R, Giacomobono S, Capacchione D, Nardelli A, Barbato F, Nappi A, Pellegrino T, Storto G
Should patients with remnants from thyroid microcarcinoma really not be treated with iodine-131 ablation?
Endocrine (ISSN: 1355-008x, 1355-008xlinking), 2013 Oct; 44(2): 426-433.

Marotta V, Ramundo V, Camera L, Del Prete M, Fonti R, Esposito R, Palmieri G, Salvatore M, Vitale M, Colao A, Faggiano A
Sorafenib in advanced iodine-refractory differentiated thyroid cancer: Efficacy, safety and exploratory analysis of role of serum thyroglobulin and FDG-PET
Clin Endocrinol (ISSN: 0300-0664, 1365-2265, 1365-2265electronic), 2013 May; 78(5): 760-767.

Grasso G, Spoto G
Plasmonics for the study of metal ion-protein interactions
Anal Bioanal Chem (ISSN: 1618-2642), 2013 Feb; 405(6): 1833-1843.

Cella L, Conson M, Pressello MC, Molinelli S, Schneider U, Donato V, Orecchia R, Salvatore M, Pacelli R
Hodgkin's lymphoma emerging radiation treatment techniques: Trade-offs between late radio-induced toxicities and secondary malignant neoplasms
Radiat Oncol Radiation Oncology (ISSN: 1748-717x), 2013 Jan 30; 8(1): 22-22.

Arena G, Attanasio F, Zhang D, Yang Y, Bartsch RA, Sgarlata C
Selective sensing of Hg2+ by a proton-ionizable calix[4]arene fluoroionophore
Anal Bioanal Chem (ISSN: 1618-2642), 2013 Jan; 405(2-3): 1133-1137.

Malgieri G, Zaccaro L, Leone M, Bucci E, Esposito S, Baglivo I, Del Gatto A, Russo L, Scandurra R, Pedone PV, Fattorusso R, Isernia C
Zinc to Cadmium Replacement in the A. thaliana SUPERMAN Cys(2)His(2) Zinc Finger Induces Structural Rearrangements of Typical DNA Base Determinant Positions
Biopolymers (ISSN: 0006-3525, 0006-6352, 0006-3525print), 2011 Nov; 95(11): 801-810.

Barbato F, Capacchione D, Nappi A, Telesca D, Tempone A, Casolino E, Nardelli A, Castaldi E, Ortosecco G, Storto G
Does remnants from low-risk differentiated thyroid cancer patients really be not treated with Iodine-131?
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2010 Oct; 37: N/D-N/D.

Abbate M, Casella G, Fiore T, Grasso G, Pellerito C, Scopelliti M, Spinella A, Pellerito L
Structural characterization of triorganotin(IV) complexes with sodium fusidate and DFT calculations
J Organomet Chem (ISSN: 0022-328x), 2010 May 1; 695(9): 1405-1413.

Pace L, Nicolai E, Klain M, Salvatore M
Diagnostic value of FDG PET/CT imaging
Q J Nucl Med Mol Im (ISSN: 1824-4785, 1824-4478, 1824-4785linking), 2009; 53(5): 503-512.

Salvatore B, Paone G, Klain M, Storto G, Nicolai E, D'Amico D, Della Morte AM, Pace L, Salvatore M
Fluorodeoxyglucose PET/CT in patients with differentiated thyroid cancer and elevated thyroglobulin after total thyroidectomy and 131I ablation
Q J Nucl Med Mol Im (ISSN: 1824-4785, 1824-4478, 1824-4785linking), 2008 Mar; 52(1): 2-8.

Caleo O, Maurea S, Klain M, Salvatore B, Storto G, Mancini M, Pace L, Salvatore M
Postsurgical diagnostic evaluation of patients with differentiated thyroid carcinoma: Comparison of ultrasound, iodine-131 scintigraphy and PET with fluorine-18 fluorodeoxyglucose
Radiol Med (ISSN: 0033-8362, 1826-6983, 1826-6983electronic), 2008 Mar; 113(2): 278-288.

Frasca F, Nucera C, Pellegriti G, Gangemi P, Attard M, Stella M, Loda M, Vella V, Giordano C, Trimarchi F, Mazzoni E, Belfiore A, Vigneri R
BRAF(V600E) mutation and the biology of papillary thyroid cancer
Endocr Relat Cancerendocrine Related Cancer (ISSN: 1351-0088), 2008; 15(1): 191-205.

Malaguarnera R, Vella V, Pandini G, Sanfilippo M, Pezzino V, Vigneri R, Frasca F
TAp73α increases p53 tumor suppressor activity in thyroid cancer cells via the inhibition of Mdm2-mediated degradation
Mol Cancer Res (ISSN: 1541-7786), 2008; 6(1): 64-77.

Cuocolo A, Milcinski M, Bischof Delaloye A
Syllabus for postgraduate specialisation in Nuclear Medicine: 2006/07 update
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2007 Mar; 34(3): 433-436.

Storto G, Liuzzi R, Klain M, Albanese C, Salvatore B, Pellegrino T, Cella L, Soricelli A, Pace L, Salvatore M
Prognostic indicators in patients with differentiated thyroid cancer receiving repeated I-131 therapies
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2006 Sep; 33: N/D-N/D.

Pace L, Klain M, Albanese C, Salvatore B, Storto G, Soricelli A, Salvatore M
Short-term outcome of differentiated thyroid cancer patients receiving a second iodine-131 therapy on the basis of a detectable serum thyroglobulin level after initial treatment
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2006 Feb; 33(2): 179-183.

Pace L, Klain M, Soricelli A, Albanese C, Salvatore B, Storto G, Salvatore M
Short Term Outcome of Differentiated Thyroid Cancer Patients with Detectable Serum Thyroglobulin after Initial Treatment Receiving a Second 131-IODINE Therapy
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2005 Sep; 32: 179-183.

Klain M, Pellegrino T, Storto G, Biondi B, Sansone V, Pagano L, Nicolai E, Della Morte A, D'Amico D, Soricelli A, Lombardi G, Pace L, Salvatore M
Postsurgical follow up of differentiated thyroid cancer using rhTSH
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2004 Sep; 31: N/D-N/D.

Biondi B, Palmieri EA, Pagano L, Klain M, Scherillo G, Salvatore M, Fenzi G, Lombardi G, Fazio S
Cardiovascular safety of acute recombinant human thyrotropin administration to patients monitored for differentiated thyroid cancer
J Clin Endocrinol Metab (ISSN: 0021-972x), 2003 Jan; 88(1): 211-214.

Klain M, Maurea S, Grivet-Fojaja MR, Acampa W, Cuocolo A, Colao A, Lombardi G, Salvatore M
Tc-99m labeled tetrofosmin and MIBI imaging in patients with thyroid or parathyroid nodules: A comparative study
J Nucl Med (ISSN: 0161-5505, 1535-5667, 1535-5667electronic), 1996 May; 37(5SUPPL.): N/D-N/D.

Klain M, Maurea S, Cuocolo A, Colao A, Marzano L, Lombardi G, Salvatore M
Technetium-99m tetrofosmin imaging in thyroid diseases: Comparison with Tc-99m-pertechnetate, thallium-201 and Tc-99m-methioxyisobutylisonitrile scans
Eur J Nucl Med (ISSN: 0340-6997, 1619-7070, 1619-7089), 1996; 23(12): 1568-1574.

Klain M, Maurea S, Lastoria S, Cuocolo A, Colao A, Salvatore M
Technetium-99m-tetrofosmin imaging of differentiated mixed thyroid cancer
J Nucl Med (ISSN: 0161-5505, 1535-5667, 1535-5667electronic), 1995 Dec; 36(12): 2248-2251.

MAUREA S, LASTORIA S, KLAIN M, GRIVETFOJAJA M, VARRELLA P, ACAMPA W, VERGARA E, MASTRO A, CONZO G, SALVATORE M
TC-99M MIBI IMAGING IN THE INITIAL DIAGNOSIS AND POST-SURGERY FOLLOW-UP OF PATIENTS WITH THYROID CANCER
Posters Tomes 1 4proceedings Of The Xvi International Cancer Congress Free Papers And, 1994; N/D: N/D-N/D.